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Cellular physiologyAbstract Complex biomolecular machinery carrying diverse glycan chains are involved in a wide
range of physiological activities including blood group determination, cancer recognition protein
stabilization and sperm–egg interaction. Diversity of glycan chains, linked to lipids and proteins
is due to isomeric and conformational modiﬁcations of various sugar residues, giving rise to unique
carbohydrate structures with a wide range of anomeric linkages. This unique and signiﬁcant struc-
tural diversity of naturally occurring oligosaccharide structures make them the best recognition
markers for countless physiological activities. This is a challenging task to explore the relationship
between biological processes and stereochemical behavior of sugar residues. Current review article
is related with the physiological signiﬁcance of glycans carrying fucose and/or sialic residues insamine;
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S10 M.R.M. Hussain et al.complex biomolecular assemblies. Both the sugar units have a diverse range of anomery and link-
ages with the penultimate sugars. The existing literature and databases did not contain comprehen-
sive information regarding structure–function relationship of glycans. Therefore, the current study
is scheduled to debate on the structure–function relationship of glycans carrying Fuc and sialic acid
in their backbone structures.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Contents
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Today the scientists (biochemists, immunologists, molecular
biologists, microbiologists, pathologists and pharmacologists)
are putting in tremendous efforts to explore the relationship
of sugars with their glycobiology. Glycoproteins and glycolip-
ids are the major constituents of biomembranes, regulating the
wide range of cellular functions including cellular differentia-
tion, interaction and communication. These diverse biological
functions of glycoconjugates are regulated by complex oligo-
saccharide structures linked with proteins and lipids in macro-
molecular assemblies. The diversity in oligosaccharide chains
attached with lipids and proteins is speciﬁcally linked with
the conformational behavior of sugar residues giving rise to
unique carbohydrate structures with a wide range of sequence
and anomeric linkage.
For example the blood group A determinant is speciﬁc with
the terminal GalNAc residue having a1-3 anomeric linkage
with the penultimate sugar. Similarly, the terminal Fuc a1-2
is linked with blood group H recognition and the Fuc a1-3
core structure is speciﬁc for allergic reactions mediated by
IgE (Becker and Lowe, 2002), while, sialic acid with a2-3 at
the non-reducing end of sugar chain is intrinsically linked with
selective adhesion and its extrinsic involvement is associated
with various pathogenic bindings (Varki, 2007). Additionally,
the speciﬁc reactivity of Fl antibody with adult erythrocytes
due to the presence of sialic acid at one terminal and Fuc at
the other terminal of glycan highlights the physiological vital-
ity of these two sugars (Kannagi et al., 1983).
According to the literature study, the sugars naturally exist
in D-form rather than L-isoform (Salam, 1991). But the fucose
sugar unlike other sugar monomers exists naturally in L-form
rather than D and found covalently linked with the D-Galact-
ose and D-GlcNAc in most of the oligosaccharide chains (by
means of a1-2, a1-3 and a1-4 anomeric linkages), while the sia-
lic acid anchors mostly at C-3, C-6 and C-8 of the Gal andGlcNAc residues (Miyoshi et al., 2008, 2010; Fujihashi et al.,
2003; Vrionis et al., 1989).
This review article discusses the physiological importance
of Fuc and sialic acid residues in complex carbohydrate struc-
tures, and then focuses on the physiological speciﬁcity of par-
ticular stereochemical features (sequence and anomeric
linkages) of Fuc and sialic acid in vital cellular phenomena.
2. Physiological efﬁcacy of fucosylated glycans
Glycans having fucose residue at their terminal and subtermi-
nal regions are involved in various cancer disorders like hepa-
tic cancer, colon cancer, cervical cancer, bladder carcinoma,
prostrate cancer, lung cancer, gastric cancer, thyroid cancer
and ovarian cancer (Miyoshi et al., 2008, 2010; Dabelsteen
et al., 1988; Fukushi et al., 1984; De-Vries et al., 1993). These
fucosylated glycans mediate the ligand adhesion with lectins
and can provide a useful basis for the diagnosis of various
pathologies. Glycoshingolipids containing different Lewis
determinant structures (Lex, Lea and Ley) are accumulated in
abundance in various human carcinomas like gastric, lung
and colon (Holmes et al., 1987; Nudelman et al., 1986; Sueyo-
shi et al., 1992; Stroud et al., 1991).
Human milk contains a-3-fucosyltransferase, which causes
fucosylation at the C-3 of GlcNAc. This alpha-3-fucosyltrans-
ferase mediates the biosynthesis of Lex related (difucosylated
and trifucosylated) glycan structures which are associated with
cancer recognition and selectin based adhesions (Dabelsteen
et al., 1988; De-Vries et al., 1993; Sarkar et al., 1997). The ligand
interaction of Lex related carbohydrate structures with selectins
can provide a useful tool for the study of metastasis in various
carcinomas. The literature study reﬂects that the Fuc moiety in
fucosylated glycans behaves as an attachment or modiﬁcation
point for the addition of fucose and various other sugar residues.
For example, the terminal addition of GalNAc with a1-3 at the
Fuc of H-antigenic determinant causes the formation of blood
Figure 1 Glycosylation patterns of Galb1-3GlcNAcb1- to form the A, B, O and Lewis blood group antigens (Mo et al., 1994).
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with a particular anomeric linkage (a1-2) at the terminal of
Lex determinant structure converts it into Ley antigenic struc-
ture and changes the overall physiology of glycan (Kobata,
1992). Hence the physiological strengths of fucosylated glycans
are speciﬁc with the sequence and anomeric linkage of Fuc sugar
within carbohydrate chains.2.1. Blood group antigens and their cellular physiology
The Lewis and ABO blood group antigens are biologically sig-
niﬁcant because these glycoepitopes generate the genetical and
biochemical speciﬁcities on the red blood cells. The experimental
study has connected the Fuc moiety with blood group ‘‘H (O)’’
speciﬁcity andN-acetyl galactosamine residue with blood group
S12 M.R.M. Hussain et al.A speciﬁcity. The complexity in ABH blood group antigens is
due to the diversity in their carrier glycan chains. The literature
data elucidate that the blood group H determinant [Fuc a 1-2]
Gal b1-3GlcNAcb1-] acts as a precursor for blood groups A,
B and Leb antigenic structures (Fig. 1) (Kobata, 1992).
The blood group A determinants have different epitopes of
lacto-series. The blood group A type 1 structure is highly ex-
pressed in goblet and columnar cells of normal fetal mucosa,
while the type 2 chains are accumulated in the human colon
carcinomas (Dabelsteen et al., 1988). The epitopes of type 1
and 2 chains of blood group A differ only in their anomeric
linkages at fucosylated Gal residues and this structural differ-
ence causes the basis for their localization in different body tis-
sues. It can also be predicted from this example that the
cellular characterization of normal and carcinomal tissues is
speciﬁcally linked with the anomeric linkages of sugar residues.
Monofucosylated and difucosylated type 2 chains of blood
group A are characterized by high concentration in tumor
tissues. This high expression of fucosylated type 2 chains in
tumor tissues links the alteration in the core structure of carbo-
hydrates with tumor development (Dabelsteen et al., 1988;
Fukushi et al., 1984).
According to the reported data, the type 2 chain structures
like Lex, Ley and sialylated Lex are also characterized by high
concentrations in colonic adenocarcinomas (Nudelman et al.,
1986; Laferte et al., 1995). The sequence and anomeric linkages
of fucosylated glycans along with their physiological functions
are given in Table 1.
2.2. The role of fucoglycans in various cellular pathologies
Fucosylation is one of the main glycosylation patterns ob-
served in cancer tissues. This glycosylation mode is controlledTable 1 Physiological involvement of glycoepitoes in cellular phen
Glycoepitope ID/
name
Structure
EP0256/Blood group
A Type 1
GalNAc(a1-3)[Fu
2)]Gal(b1-3)GlcN
R
EP0260/Blood group
A Type 1
(Difucosylated
glycan)
GalNAc(a1-3)[Fu
2)]Gal(b1-3)[Fuc(
4)]GlcNAc(b1-)-R
EP0257/Blood group
A Type 2
GalNAc(a1-3)[Fu
2)]Gal(b1-4)GlcN
R
EP0261/Blood group
A Type 2
(Difucosylated
glycan)
GalNAc(a1-3)[Fu
2)]Gal(b1-4)[Fuc(
3)]GlcNAc(b1-)-R
EP0258/Blood group
A Type 3
GalNAc(a1-3)[Fu
2)]Gal(b1-3)GalN
R
EP0262/Blood group
B Type 2
Gal(a1-3)[Fuc(a1
2)]Gal(b1-4)GlcN
R
EP0093/ Lewisx Gal(b1-4)[Fuc(a1
3)]GlcNAc(b1-3)G
4)[Fuc(a1-3)]GlcN
Rby different fucosyltransferases, which in turn is regulated by
several genes in the body. Fucosylated proteins are the well-
known cancer markers in the body. Alpha-fetoprotien is one
of such proteins involved in different pathological conditions
of the liver. It is also observed from the literature that the
fucosylated fetoprotein is a renowned hepatocarcinomal mar-
ker and a liver cirrhosis determinant. The a1-6 fucosyltransfer-
ase has its signiﬁcant involvement in the regulation of core
fucosylation reaction. (Miyoshi et al., 1999, 2010).
Schistosoma mansoni is a signiﬁcant pathogen which causes
schistosomiasis disease in humans. The egg antigens of S. man-
soni has a receptor binding with the C-type lectin (DC-SIGN)
through the a1-3 fucosylated Lex and LacdiNAc GalNAcb1-
4(Fuca1-3)GlcNAc structures (Huang et al., 2001).
Bronchiectasis is an obstructive lung disease, linked with
fucolipids for its characterization. According to the documented
study, this bronchiectasis disease is associated with different dis-
orders and infectionsof staphylococcus species.The glycan-aldal-
tol chains isolated from the respiratory mucins of bronchiectasis
patient are Gal(b1-4)[Fuc(a1-3)]GlcNAc(b1-3)Gal(b1-4)[Fuc
(a1-3)]GlcNAc(b1-3)Gal(b1-3)GalNAc-ol; Fuc(a1-2)Gal (b1-3)
[Fuc(a1-4)]GlcNAc(b1-3)Gal(b1-3)[Gal(b1-4)GlcNAc(b1-6)]
GalNAc-ol and Fuc(a1-2)Gal(b1-4)[Fuc(a1-3)]GlcNAc(b1-3)
[Gal(b1-4)GlcNAc(b1-6)]Gal(b1-3)GalNAc-ol. These fucosy-
lated glycan chains provide the range of determinant structures
for bronchiectasis (Van-Kuik et al., 1991).
Moreover, the Fuc rich glycopeptides and glycoconjugates
are also recognized in the urine of fucosidosis patients. Struc-
tures obtained from the urine of fucosidosis are Gal(b1-4)
[Fuc(a1-3)]GlcNAc(b1-2)Man(a1-6)Man(b1-4)GlcNAc and
Gal(b1-4)[Fuc(a1-3)]GlcNAc(b1-2)Man(a1-3)Man(b1-4)Glc-
NAc. Both the structures have Fuc at the C-3 position of
GlcNAc, which is further attached with human throughomena.
Physiological contexts and references
c(a1-
Ac(b1-)-
Blood group A determinants are potently expressed
in columnar cells of normal fetal mucosa (Dabelsteen
et al., 1988; Mo et al., 1994)
c(a1-
a1-
Blood group A variants with fucosylated domains are
potently expressed in columnar cells of normal fetal
mucosa (Dabelsteen et al., 1988)
c(a1-
Ac(b1-)-
Complex carbohydrate structures act as carrier for
human carcinomas (Dabelsteen et al., 1988; Fukushi
et al., 1984; Clausen et al., 1986)
c(a1-
a1-
Fucosylated structures have their involvement in
human normal colon and colon tumor (Dabelsteen
et al., 1988; Fukushi et al., 1984; Clausen et al., 1986)
c(a1-
Ac(a1-)-
Involvement of blood group epitopes in bladder
carcinoma, cervical epidermal carcinoma and colon
carcinoma (Dabelsteen et al., 1988; Clausen et al.,
1986)
-
Ac(b1-)-
Detection of Oncodevelopment changes in rat and
human colon cancer cells on the basis of blood group
variant (Dabelsteen et al., 1988; Laferte et al., 1995)
-
al(b1-
Ac(b1-)-
Recognition of human adrenocarcinomas by Lex
expression (De-Vries et al., 1993; Holmes et al., 1987)
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difference at the anomeric linkages of mannose in both iso-
lated structures reﬂects that the Fuc moiety may affect the
anomeric environment of penultimate sugar residues within
glycans.
The experimental study proved that the BR55-2 monoclonal
antibodyhas the potent binding speciﬁcity for theYdeterminant
[Fuca1-2Galb1-4GlcNAc(Fuca1-3)b1-3Galb1-4Glcb1-1Cer]
and the Y-related difucosylated determinant structure [Gal a1-3
Gal (Fuc a1-2) b1-4GlcNAc(Fuc a1-3) b 1-3Gal b 1-4Glc b 1-1
Cer], which are identiﬁed in human gastric adenocarcinoma cell
line KATO III (Blaszczyk-Thurin et al., 1987).
2.3. Involvement of fucose sugar in lectin adhesion
Lectins, the N-linked glycoproteins are engaged in regulating
several important physiological mechanisms like cell death, im-
mune system homeostasis, and control of tumorigenesis. All
lectins having the same nature as that of Iris lectin can be dis-
criminated on the basis of their interactions with detailed car-
bohydrate structures. For example Lima Bean Lectin (LBL)
has strong binding potency for the blood group A trisaccha-
ride structure GalNAc a1-3(Fuca1-2)Gal having Fuc as a side
sugar moiety. This agglutination pattern of LBL can be dimin-
ished by removing the Fuc sugar from the blood group A var-
iant. Similarly the binding interaction of iris lectin with blood
group A is diminished due to the steric hindrance of Fuc resi-
due. The steric hindrance of Fuc residue provides the basis for
the failure in blood group A agglutination and can be used as a
valuable tool for the characterization and diagnosis of various
cellular pathologies (Mo et al., 1994).
Dilochos biﬂorus agglutinin (DBA) has a strong binding
speciﬁcity for the Forssmann disaccharide (GalNAca1-3Gal-
NAc). But this binding interaction is found weaker in the case
of blood group A trisaccharide. The poor binding ability ofFigure 2 Carbohydrate trisaccharide structure and its ligand
complexation with lectin (Hamelryck et al., 1999).blood group A determinant suggests that the C-2 hydroxyl
group of penultimate Gal residue is the vital locus for the lectin
binding. The binding capability of DBA is abolished by replac-
ing the C-2 hydroxyl group of Gal with Fuc sugar (Fig. 2)
(Hamelryck et al., 1999).3. Sialic acid chemistry and physiological signiﬁcance of
sialylated glycans
Sialic acid contains backbone structure of 9 carbons including
carboxylic acid moiety at the C-1 position. Variations in ano-
meric linkages and the substitutions at the C-4, C-5, C-7, and
C-8 and C-9 positions reﬂect the diverse nature of sialic acid
moiety (Fig. 3). N-Acetyl neuraminic acid (Neu5Ac) and N-
glycolyl neuraminic acid (Neu5Gc) are the two main sialic acid
residues found in mammalian glycans. Additional oxygen
atom in Neu5Gc distinguishes this sialic acid unit from
Neu5Ac and may be the cause of its localization in different
species (Neu5Gc is the modiﬁed form of Neu5Ac which has
been diminished in human species during genetic mutation).
In fact, the abnormal occurrence of GM2 gangliosides (N-acet-
yl and N-glycolyl species of GM2) is localized in carcinomas by
the recognition of N-acetyl and N-glycolyl groups of sialic
acids. The literature study highlights that the Neu5Ac moiety
is attached mostly with the Gal and GlcNAc in oligosaccharide
chains. Sialic acid causes the increase in the strength of charge
density on the whole glycan chain due to the presence of its
carboxylic acid moiety. The carboxylic acid moiety, N-acetam-
ido group along with the hydroxyl groups are reported in dif-
ferent types of cellular interactions in immunity, homoeostasis
and inﬂammation (Chen and Varki, 2010; Varki, 2007).
Selectins are known as sialic acid binding proteins and
engaged in immunity and inﬂammations related cellular
phenomena. The ligand interactions of leukocytes with endo-
thelial-selectin (E-selectin) and platelet selectin (P-selectin)
are mediated through sialic acid moieties. So the recognition
of all types of selectins is mediated with sialic acid residues
(Chen and Varki, 2010; Varki, 1994).
Sialylated Lex was potently expressed in the malignant tu-
mors of epithelial origin and experimental study demonstrated
that the carcinoma having sialyl Lex could bind with the
E-selectin on activated endothelial cells. Sialylated mucins of
circulating carcinomas initiate the interactions with platelets
and leukocytes by mimicking natural selectin ligands. Hence
the existence and distribution of malignant cells in blood-
stream are mediated by the platelets and leukocytes. It is also
found that the use of heparin as an inhibitor of P- and L-selec-
tin causes the remarkable decrease in metastasis (Varki, 1994;
Varki and Varki, 2002).
Siglecs (sialic-acid-recognizing Ig-superfamily lectins) re-
quired sialic acid with speciﬁc anomeric linkage for their phys-
iological actions. For example, CD22 (Siglec-2) is a known
inhibitor of B cell receptor (BCR) signaling due to O-acetyla-
tion at C-9 of the sialic acid having a2-6 linkage (Cariappa
et al., 2009). Similarly, the CD33rSiglecs are involved in the
recognition of pathogens having sialic acid residues. Docu-
mented study elucidates that the Siglecs adhesion is mediated
by the recognition of carboxylic acid charge density, N-acetyl
group and the hydroxyl groups of C-4, C-5, C-7, C-8 and
C-9 in the sialic acid parent molecule (Cariappa et al., 2009;
Vyas et al., 2005; Varki, 2007).
Figure 3 The functional groups are pointed out in stereochemical structure of N-acetyl neuraminic acid (NeuAc) and N-glycolyl
neuraminic acid (NeuGc).
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components having sialic acid sugar residues in their parent
chain. The cell signal transduction is regulated by these plasma
membrane components of glycolipids. More than 60 ganglio-
sides are known, which have different sequence, anomery
and linkage of sialic acid with the vicinal sugars. These gan-
gliosides being part of cell membrane and extracellular matrix
mediate different physiological actions like nerve cells interac-
tion, recognition and communication. The GM1, GD1a,
GD1b, GT1b, GM2, GM3, GD2, GD3 and GT1c are the com-
mon gangliosides present in the central and peripheral nervous
system. These gangliosides are homologous to each other but
have different number of sialic acid residues in their glycan
chain. The GM1, GM2 and GM3 have single sialic acid resi-
due and are known as monosialogangliosides. While the
GD1a, GD1b, GD3 and GD2 are disialogangliosides, due to
the presence of two sialic acid moities in their glycan struc-
tures. Similarly the GT1 contains three and GQ1 contains four
neuraminic acid residues. Most of the mono-, di-, and tri-sia-
logangliosides are biosynthesized by GM3 ( Figs. 4 and
Fig. 5). The change in the number and sequence of neuraminic
acid residues in complex carbohydrate structures may provide
the basis for diverse cellular physiologies in different biological
systems (Kusunoki et al., 1993; Abregu´ et al., 2002; Hidari
et al., 1993; Vrionis et al., 1989; Kotani et al., 1993; Yamaguchi
et al., 1990).
GM1 and GM2 are the valuable markers in the early detec-
tion of diabetic complications. During short term diabetes in
rats, the change in expressions of GM1 and GM2 is lead by
the microscopic hepatocellular modiﬁcations (Abregu´ et al.,
2002). It is also observed that the extension in GM2 chainlength causes cancer-associated modiﬁcations in gastric
mucosa. N-acetyl- and N-glycolyl GM2 antigens are observed
in non-seminomatous and seminomatous germ tumors,
respectively. The N-glycolyl GM2 is linked with the level of
differentiation of non-seminomatous germ cell tumors, chorio-
carcinoma, and teratocarcinoma, which have a positive occur-
rence of N-glycolyl GM2 as compared with the N-acetyl GM2
(Miyake et al., 1990). GM2 and GD2 gangliosides are potently
expressed on the melanoma, astrocytoma, neuroblastoma, and
leukemia cell lines, and the detection of these glycolipids is
done by using 3-207 monoclonal antibodies (Miyake et al.,
1990; Yamaguchi et al., 1990; Nakamura et al., 1984).
Disialogangliosides, GD3 and GD2 are expressed in large
concentrations on the cellular surface of human melanomas.
Monoclonal antibodies (Mabs), which have binding potency
for the GD3 and GD2, restrict the attachment of melanoma
and neuroblastoma with various substrate adhesive proteins
like ﬁbronectin, collagen, vitronectin and laminin (Yamaguchi
et al., 1990; Longee et al., 1991; Iwamori and Nagai, 1979;
Cheresh et al., 1986).
GD1c is an important ganglioside of T cells synthesized by
asialo-GM1 [Gal(b1-3)GlcNAc(b1-4)Gal(b1-4)Glc(b1-1)Cer].
The other GM1 derivatives, like GM1b (NeuAc and NeuGc)
and GD1a are also detected in large quantity in T cells. The
structures containing the GM1 core structure like Gal-Lac-
NAc-GM1, a-Gal-(LacNAc)2-GM1, and sialyl-LacNAc-
GM1 are observed in high concentration in B-cells (Iwamori
and Nagai, 1979).
GD1b is recognized with the other gangliosides like GQ1b
and GM1 in human and rat nervous systems. This glycolipid
(GD1b) is characterized on the granular cell bodies surface
Figure 4 The biosynthesis of different monosialogangliosides (GM1, GM2, GM3 and GD1a).
Physiological signiﬁcance of Fuc and Sialic acid containing glycans in the body S15by means of antibodies. Serum antibodies which have been
localized in autoimmune neuropathies can be used for the
characterization of GM1 and GD1b in the human peripheral
nervous system. GD1b antigen is expressed on neurons and
paranodal myelins in the peripheral nervous system while the
GM1 is localized with neurons in dorsal root ganglia and sym-
pathetic ganglia (Kusunoki et al., 1993, 1994).
The Immunochemical study of pig cochlea highlights that
the glycoconjugates of ganglio-series having GM3, GD3 andGD2 are potently expressed in the neuronal ﬁbers spiral gan-
glions, and stria vascularis. These structures are completely ab-
sent in the tectorial membrane (TM) and Corti’s organ of Pig
(Hozawa et al., 1993).
Human milk gangliosides contain the GM1 and GM3
structures and block the adhesion of E. coli with Caco-2 cells.
It is also analyzed from the literature that the bovine milk
gangliosides have less blocking tendency for E.coli
adhesion. The rate of adhesion of E. coli in the presence of
Figure 5 The biosynthesis of different sialogangliosides like GD1, GD2 and GD3. The GM3 ganglioside acts as precursor for the
formation of the di and trisalylated gangliosides.
S16 M.R.M. Hussain et al.monosialoganglioside 1 (GM1) is found to be less than 20%.
The adhesion of E. coli is observed to be more than 30% for
the monosialoganglioside 3 (GM3). However, the blocking ef-
fect of disialoganglioside 3 (GD3) is found to be less than that
of GM3 (Nakamura et al., 1984; Idota and Kawakami, 1995).
Similarly, bacterial toxins cause the number of diseases like
diarrheal disease due to their recognition by GM1 epitopic do-
mains and its homologs. Vibrio-cholera secretes the Cholera-toxin whose B-subunit has strong binding speciﬁcity for the
GM1 ganglioside. The same preference is found for the
GD1b and GT1b [Neu5Ac(a2-3)Gal(b1-3)GalNAc(b1-4)
[Neu5Ac(a2-8)Neu5Ac(a2-3)]Gal(b1-4)Glc(b1-1)Cer]. The
additional NeuAc causes the reduction in binding afﬁnity
due to steric hindrance. It is also shown in the literature that
the N-acetyl group of neuraminic acid in GM1 is not necessary
for its binding with the cholera-toxin B-subunit. The
Table 2 Functional regions of sialylated glycans with their biological efﬁcacy.
Glycan ID/
name
Glycan sequence Functional region Function/reference
G00168/
GalNAc-
GD1a
GalNAc(b1-4)[Neu5Ac(a2-3)]Gal(b1-
3)GalNAc(b1-4)[Neu5Ac(a2-3)]Gal(b1-4)Glc(b1-
1)Cer
GalNAc(b1-4)[Neu5Ac(a2-
3)]Gal(b1-1
1. Guillain-Barre syndrome (Kusunoki et al., 1994)
2. Brain cancer and related pathophysiology (Idota and
Kawakami, 1995; Merritt et al., 1994; Grassi et al., 1990;
Yasukawa et al., 1995)
G00109/
GM2
GalNAc(b1-4)[Neu5Ac(a2-3)]Gal(b1-4)Glc(b1-
1)Ceramide
GalNAc(b1-4)[Neu5Ac(a2-
3)]Gal(b1-4)Glc(b1-1
Human germ cell tumors (Morrison et al., 1991)
EP0052/N-
Glycolyl
GM2
GalNAc(b1-4)[Neu5Gc(a2-3)]Gal(b1-4)Glc(b1-
1)Cer
GalNAc(b1-4)[Neu5Gc(a2-
3)]Gal(b1-)
Human germ cell tumors (Morrison et al., 1991)
EP0061/
GD2
GalNAc(b1-4)[Neu5Ac(a2-8)Neu5Ac(a2-
3)]Gal(b1-4)Glc(b1-1)Cer
GalNAc(b1-4)[Neu5Ac(a2-
8)Neu5Ac(a2-3)]Gal(b1-
4)Glc(b1-1)Cer
1. Human neuroectodermal tumor (Eto and Shinoda,
1982)
2. Lung carcinoma (Watarai et al., 1994)
3. Binding interaction of human melanomas and
neuroblastomas to extracellular proteins (Svennerholm
et al., 1973; Yu et al., 1983)
EP0050/
GM1
Gal(b1-3)GalNAc(b1-4)[Neu5Ac(a2-3)]Gal(b1-
4)Glc(b1-1)Cer
Gal(b1-3)GalNAc(b1-
4)[Neu5Ac(a2-3)]Gal(b1-
4)Glc(b1-1)Cer
1.Recognition of GM1 in small cell lung carcinoma cell
lines and tissues (Watarai et al., 1994)
2. Prostate cancer and localization of human peripheral
nervous system (Saito et al., 2005; Hidari et al., 1993;
Vrionis et al., 1989)
2. Guillain-Barre´ syndrome (Kusunoki et al., 1994)
G03973 Gal(a1-3)Gal(b1-4)GlcNAc(b1-6)[Neu5Ac(a2-
3)Gal(b1-4)Glc(b1-3)]Gal(b1-4)GlcNAc(b1-
3)Gal(b1-4)Glc(b1-1)Ceramide
Neu5Ac(a2-3)Gal Inﬂuenza virus A/X-31 (H3N2) binding speciﬁcity with
sialic acid Gal (Suzuki et al., 1986)
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S18 M.R.M. Hussain et al.de-N-acetyl-neuraminic acid GM1 [Gal(b1-3)GalNAc
(b1-4){Neu (a2-3)}Gal(b1-4)Glc(b1-1)Cer] of bovine brain
have binding preference for the DM2-1 mouse monoclonal
antibody and Cholera-toxin B subunit. So these de-N-acety-
lated gangliosides are bioactive macromolecules having their
signiﬁcant role in the nervous system (Merritt et al., 1994;
Grassi et al., 1990; Yasukawa et al., 1995).
GM1 has its involvement in neuronal plasticity and repair
mechanisms, and release of neurotrophins in brain. Besides
that the GM1 derivatives bind with the T cells resulted in
the down regulation of their surface protein CD4, and can re-
duce human herpesvirus 7 infection (Morrison). The further
physiological functions performed by sialic acid containing ac-
tive domains of glycans are given in Table 2.
4. Databases annotation
Different glycan databases like Glycoepitope, Kegg, Glycosu-
ite, Glycome DB, Complex Carbohydrate Structural Database
(CCSD), GlycoMaps, Glycobase and Glycoscience are pub-
licly present to evaluate the implications of sugar anomeric
linkages in speciﬁc recognition activities. These databases
provide the information about glycan structures and their
functional diversity, but are still limited about the structure–
function relationship of sugar motifs.
The statistical detail of these databases is given below:
Glycoepitope (http://www.glyco.is.ritsumei.ac.jp/epitope/)
have 146 glycoepitope entries. Each epitopic ID starts with
English Capital letter EP. The information given against each
entry contain data like Epitope ID, Sequence, Aliases, History,
Molecular weight, Species, compositions and receptor
explanation.
Kegg database (http://www.genome.jp/kegg/) contains
10969 glycan entries some of which are methylated, phosphor-
ylated and sulfated. Kegg database gives information about
structural ID, Composition, Mass, Structure, Class, biosyn-
thetic pathway, orthology, enzyme details and KCF data of
glycan chains. Each Kegg glycan entry starts with the Alpha-
betical letter G.
Eurocarb bank (www.eurocarbdb.org) consists of 13,457 de-
tailed glycan sequences of which 1 HPLC, 89 Mass Spectrom-
etry, and 0 NMR analyses based glycan structures are present.
Bacterial Carbohydrate Structure Database (BCSDB) en-
closes 9506 glycan motifs. Each glycan entry contains the
information like BCSDB ID, Bibliography, (Sub) structure,
Microorganism, NMR signals.
Glycoscience database (http://www.glycosciences.de/
sweetdb/) gives details of Structures, Theoretical Mass
peaks, NMR Data, Taxonomy etc. This database contains
14857 different sugar structures having O-glycans (505),
N-glycans (3415), and glycolipids (560).
GlycoMaps (http://www.glycosciences.de/modeling/
glycomapsdb/) is another database which contains 2585
conformational maps. This database deals with confor-
mational maps of disaccharide motifs. It is linked with
other databases like Glycosciences database for further
details like pdb ﬁles, mass spectra, NMR spectra etc.
Consortium for Functional Glycomics (CFG) (www.
functionalglycomics.org) database encloses 7500 entries. Each
entry holds structural as well as chemical information.
Glycome DB (http://www.glycome-db.org/showMenu.
action?major=database) gives information containing allstructures and annotations. It provides details like image of
the structure, entries in other databases for the structure,
known carbohydrate motifs and encoding of the structure.5. Conclusion
The structure–function relationship of complex carbohydrates
is attracting the attention of scientists working all over the
world in the ﬁeld of science and technology. And it is now clear
from the above discussion that the particular stereochemical
features of glycans regulate a wide range of physiological func-
tions in the body. It is also observed that a slight change in the
structure of the glycan motif can cause a remarkable alteration
in their physiological functions. The most prominent example
is the involvement of neuramic acid derivatives in cancer pro-
gression. The structural difference between the two glycolipids,
GalNAc(b1-4)[Neu5Ac(a2-3)]Gal(b1-) and GalNAc(b1-4)
[Neu5Gc(a2-3)]Gal(b1-) is provided by the acetyl and glycolyl
groups attached with the C-5 of Neuraminic acid in the glycan
chain. The glycan structure carrying the acetyl group is linked
with hepatic and brain cancers, while the glycolylated glycan
structure has its physiological role in brain cancer only
(Vrionis et al., 1989).
Similarly, the ligand interaction of blood group variants
with lectins is also signiﬁcantly affected by replacing or adding
the fucose sugar with speciﬁc anomeric linkage. The acceler-
ated research in glycobiology is corroborating the signiﬁcance
of our study on glycans. This type of study can mediate the ba-
sis for the diagnosis of various cellular pathologies. The study
can provide the useful tool for the prediction of various dis-
eases and their diagnosis.Acknowledgments
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